Table 2: Candidate vaccines under development using different platforms.
Platform |
Candidate vaccines (no. and %) |
||
PS. |
Protein subunit |
54 |
32% |
VVnr |
Viral Vector (non-replicating) |
21 |
13% |
DNA |
DNA |
16 |
10% |
IV |
Inactivated Virus |
22 |
13% |
RNA |
RNA |
41 |
24% |
VVr |
Viral Vector (replicating) |
4 |
2% |
VLP |
Virus Like Particle |
6 |
4% |
VVr + APC |
VVr + Antigen Presenting Cell |
2 |
1% |
LAV |
Live Attenuated Virus |
2 |
1% |
VVnr + APC |
VVnr + Antigen Presenting Cell |
1 |
1% |
BacAg-SpV |
Bacterial antigen-spore expression vector |
1 |
1% |
Total |
170 |
Ref: WHO COVID-19 vaccine tracker and landscape (accessed on August 5, 2022)